Ricardo Gazzinelli to Spike Glycoprotein, Coronavirus
This is a "connection" page, showing publications Ricardo Gazzinelli has written about Spike Glycoprotein, Coronavirus.
Connection Strength
0.622
-
Almeida GG, Pinto JA, Pinto PM, da Silva LB, Andrade LAF, Valiate BVS, Zini N, Bagno FF, Rivelli GG, Louren?o KL, Souza JPC, Gomes IP, de Castro NS, Maia ALC, de Carvalho AF, Alves JC, de Castro JT, Li G, da Rocha Fernandes G, Alves PA, Diniz RC, Daher AB, de Souza RP, Teixeira SMR, Fernandes APSM, Gazzinelli RT, da Costa Santiago H. Safety and immunogenicity of SpiN-Tec, a T-cell based RBD-Nucleocapsid chimeric vaccine for COVID-19. Vaccine. 2025 Oct 03; 64:127756.
Score: 0.227
-
Hojo-Souza NS, de Castro JT, Rivelli GG, Azevedo PO, Oliveira ER, Faustino LP, Salazar N, Bagno FF, Carvalho AF, Rattis B, Louren?o KL, Gomes IP, Assis BRD, Piccin M, Fonseca FG, Durigon E, Silva JS, de Souza RP, Goulart GAC, Santiago H, Fernandes APS, Teixeira SR, Gazzinelli RT. SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern. Vaccine. 2024 12 02; 42(26):126394.
Score: 0.212
-
Castro JT, Azevedo P, Fumagalli MJ, Hojo-Souza NS, Salazar N, Almeida GG, Oliveira LI, Faustino L, Antonelli LR, Mar?al TG, Augusto M, Valiate B, Fiorini A, Rattis B, Ramos SG, Piccin M, Nonato OC, Benevides L, Magalh?es R, Cassaro B, Burle G, Doro D, Kalil J, Durigon E, Salazar A, Caballero O, Santiago H, Machado A, Silva JS, da Fonseca F, Fernandes AP, Teixeira SR, Gazzinelli RT. Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein. Nat Commun. 2022 08 17; 13(1):4831.
Score: 0.183